Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

The combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including ...

GSK announced today that Health Canada has approved Blenrep (belantamab mafodotin for injection) in combination with ...

European Union approves GSK’s Blenrep combinations to treat relapsed/refractory multiple myeloma: London, UK Saturday, July 26, 2025, 11:00 Hrs [IST] GSK plc announced the appro ...

The US Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA) for ...

The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood ...

GSK (NYSE:GSK) announced on Thursday that EU regulators approved two combination therapies involving its antibody drug ...

However, yesterday GSK announced that the FDA has extended the review period for Blenrep to give the agency time to review ...

And other biotech news brought to you by The Readout.

GSK’s Blenrep (belantamab mafodotin) combinations have been approved by the European Commission (EC) to treat adults with relapsed or refractory multiple myeloma.

In an import contrast to events in the USA, UK pharma major GSK late Thursday announced the approval of Blenrep (belantamab ...

FDA extends Blenrep combo review to October to assess more data from Phase 3 trials in relapsed or refractory multiple myeloma.